NYSE - Nasdaq Real Time Price USD

Kenvue Inc. (KVUE)

Compare
22.99 -0.03 (-0.15%)
As of 12:07 PM EDT. Market Open.
Loading Chart for KVUE
DELL
  • Previous Close 23.02
  • Open 22.83
  • Bid 23.02 x 900
  • Ask 23.03 x 800
  • Day's Range 22.77 - 23.06
  • 52 Week Range 17.67 - 23.55
  • Volume 7,199,678
  • Avg. Volume 17,355,601
  • Market Cap (intraday) 44.02B
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) 40.32
  • EPS (TTM) 0.57
  • Earnings Date Oct 24, 2024 - Oct 28, 2024
  • Forward Dividend & Yield 0.82 (3.56%)
  • Ex-Dividend Date Aug 14, 2024
  • 1y Target Est 22.15

Kenvue Inc. operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands. The Skin Health and Beauty segment provides face and body care, hair, sun, and other care products under the Neutrogena, Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Rogaine, and OGX brand names. The Essential Health segment offers oral and baby, women's health, wound, and other care products under the Listerine, Johnson's, Band-Aid, and Stayfree, o.b., tampons, Carefree, and Desitin Diaper Rash brands. The company was incorporated in 2022 and is headquartered in Skillman, New Jersey.

www.kenvue.com

22,000

Full Time Employees

December 31

Fiscal Year Ends

Recent News: KVUE

View More

Performance Overview: KVUE

Trailing total returns as of 9/23/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

KVUE
10.06%
S&P 500
19.89%

1-Year Return

KVUE
16.51%
S&P 500
32.37%

3-Year Return

KVUE
9.97%
S&P 500
40.81%

5-Year Return

KVUE
9.97%
S&P 500
40.81%

Compare To: KVUE

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: KVUE

View More

Valuation Measures

Annual
As of 9/20/2024
  • Market Cap

    44.09B

  • Enterprise Value

    51.68B

  • Trailing P/E

    40.39

  • Forward P/E

    18.66

  • PEG Ratio (5yr expected)

    6.34

  • Price/Sales (ttm)

    2.86

  • Price/Book (mrq)

    4.33

  • Enterprise Value/Revenue

    3.34

  • Enterprise Value/EBITDA

    20.33

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    7.23%

  • Return on Assets (ttm)

    6.97%

  • Return on Equity (ttm)

    10.55%

  • Revenue (ttm)

    15.48B

  • Net Income Avi to Common (ttm)

    1.12B

  • Diluted EPS (ttm)

    0.57

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.01B

  • Total Debt/Equity (mrq)

    84.56%

  • Levered Free Cash Flow (ttm)

    1.99B

Research Analysis: KVUE

View More

Earnings Per Share

Consensus EPS
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Analyst Price Targets

18.00 Low
22.15 Average
22.99 Current
25.00 High
 

Company Insights: KVUE

Research Reports: KVUE

View More
  • Looking for more favorable entry point

    Kenvue Technologies Inc., formerly part of Johnson & Johnson, is a pure-play consumer health company. The company has three segments: Self Care, Skin Health & Beauty, and Essential Health. Major brands include Tylenol, Nicorette, Zyrtec, Neutrogena, Aveeno, Listerine, and Band-Aid. The company has 22,000 employees. KVUE shares are a component of the S&P 500.

    Rating
    Price Target
     
  • Major indices are mixed at midday. Crude oil is down 3%. Wall Street is

    Major indices are mixed at midday. Crude oil is down 3%. Wall Street is waiting on the key inflation report coming tomorrow. Any surprises will not be appreciated. We expect the CPI report to show a slight tick down, meaning that inflation is tracking lower, as the Fed wants. Markets have priced in a Fed rate cut at the meeting next week.

     
  • Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We Cover

    In this edition, Bellway builds an appealing position; Kenvue is looking fairly healthy; Rockwell engineers a most; and Rheinmetall, Disney, and New Fortress Energy.

     
  • Kenvue Earnings: Turnaround Story Begins as Investment Behind Brands Delivers Margin Growth

    Kenvue is the world’s largest pure-play consumer health company by sales, generating $15 billion in annual revenue. Formerly known as Johnson & Johnson’s consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of silos within consumer health, such as cough, cold and allergy care, pain management, face and body care, and oral care, as well as women’s health. Its portfolio includes a wide array of some of the most well-known brands in the space, including Tylenol, Listerine, Johnson’s, Aveeno, and Neutrogena. Despite playing in a fragmented industry with intense competition and ever-changing consumer preferences, many of Kenvue’s brands are the global leader in their respective segment thanks to their strong brand power.

    Rating
    Price Target
     

People Also Watch